EcoDrugPlus

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSAPEG00000011776
Gene Symbol: GHSRA
1 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSAPEG00000016318
Gene Symbol: GUCY1A1
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSAPEG00000016368
Gene Symbol: GUCY1A2
2 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSAPEG00000016513
Gene Symbol: GUCY1B1
1 Cross references
211 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSAPEG00000023220
Gene Symbol: HSP90AA1.1
1 Cross references
305 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSAPEG00000023211
Gene Symbol: HSP90AA1.2
1 Cross references
317 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSAPEG00000009785
Gene Symbol: HSP90AB1
1 Cross references
333 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSAPEG00000009394
Gene Symbol: HMGB1B
1 Cross references
512 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSAPEG00000005268
Gene Symbol: HRH1
2 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSAPEG00000008522
Gene Symbol: HRH2
1 Cross references
181 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSAPEG00000012722
Gene Symbol: HRH2A
1 Cross references
192 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSAPEG00000003218
Gene Symbol: HDAC1
1 Cross references
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).